Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308123 | 1.00 | RNPEP (0.31) | RNPEP | |
| SCHEMBL5183309 | 0.84 | — | — | |
| SCHEMBL5183310 | 0.84 | — | — | |
| SCHEMBL1067580 | 0.82 | — | — | |
| SCHEMBL1067579 | 0.82 | — | — | |
| SCHEMBL1067524 | 0.79 | ALDH1A1 (0.31) | — | |
| SCHEMBL4424795 | 0.77 | CES2 (0.32) | — | |
| SCHEMBL4424793 | 0.77 | CES2 (0.32) | — | |
| SCHEMBL15955974 | 0.77 | ALDH1A1 (0.38) | — | |
| SCHEMBL15909004 | 0.73 | CES2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 591 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261599-A1 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | FACTOR BIOSCIENCE INC. | 2020-08-20 | — | — | US | claimed |
| US-20150119351-A1 | THERAPY OF TUMORS AND INFECTIOUS AGENTS DEFICIENT IN METHYLTHIOADENOSINE PHOSPHORYLASE | LUBIN ADAM (US) | 2015-04-30 | — | — | US | claimed |
| US-8796241-B2 | Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase | LUBIN ADAM (US) | 2014-08-05 | — | — | US | claimed |
| US-20120094947-A1 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2012-04-19 | — | — | US | claimed |
| EP-2192905-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | Lubin, Adam (US) | 2010-06-09 | — | — | EP | claimed |
| US-20090326196-A1 | Proteins Containing a Fluorinated Amino Acid, and Methods of Using Same | TRUSTEES OF TUFTS COLLEGE | 2009-12-31 | — | — | US | claimed |
| WO-2009032057-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2009-03-12 | — | — | WO | claimed |
| EP-1993582-A2 | PROTEINS CONTAINING A FLUORINATED AMINO ACID, AND METHODS OF USING SAME | Trustees Of Tufts College (US) | 2008-11-26 | — | — | EP | claimed |
| WO-2007084527-A2 | PROTEINS CONTAINING A FLUORINATED AMINO ACID, AND METHODS OF USING SAME | TRUSTEES OF TUFTS COLLEGE (US) | 2007-07-26 | — | — | WO | claimed |
| US-20050175550-A1 | Trifluoromethionine for preventing and/or treating intraoral diseases; bad breath, periodontal disease, alveolar pyorrhea; bactericide | KYUSHU TLO COMPANY, LIMITED (JP) | 2005-08-11 | — | — | US | claimed |
| EP-1358877-A1 | COMPOSITIONS FOR ORAL USE | Koga, Keiko (JP) | 2003-11-05 | — | — | EP | claimed |
| US-12612440-B2 | Modified bovine G-CSF polypeptides and their uses | ELANCO US INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4716693-A2 | PHARMACEUTICAL COMPOSITIONS FOR ANTIBODIES AND MAKING AND USING THE SAME | INVETX, INC. (US) | 2026-04-01 | — | — | EP | disclosed |
| WO-2024243322-A9 | PHARMACEUTICAL COMPOSITIONS FOR ANTIBODIES AND MAKING AND USING THE SAME | INVETX, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2024243322-A2 | PHARMACEUTICAL COMPOSITIONS FOR ANTIBODIES AND MAKING AND USING THE SAME | INVETX, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-1992018118-A1 | MEDICAMENTS | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY AND OREGON STATE UNIVERSITY (US) | 1992-10-29 | — | — | WO | disclosed |
| US-5100786-A | Gene capable of enhancing S-adenosyl-L-methionine accumulation and process for producing S-adenosyl-L-methionine using the same | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1992-03-31 | — | — | US | disclosed |
| US-4820692-A | PARASITICIDES, FUNGICIDES | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND OREGON STATE UNIVERSITY (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0233031-A2 | Methylthioribose analogues, their preparation and use as medicinal agents and biocides | STATE OF OREGON BY AND THROUGH OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OREGON HEALTH SC. UNIV. AND OREGON STATE UNIV. (US) | 1987-08-19 | — | — | EP | disclosed |
| US-4183786-A | FROM GYLCINE BY CULTURING MUTANT OF NOCARDIA | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1980-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326196-A1 | Proteins Containing a Fluorinated Amino Acid, and Methods of Using Same | DNPEP, NPEPPS, ANPEP | RNPEP 15/4885 |
| US-20200261599-A1 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | STING1, MITF, RARA | RNPEP 338/4885 |
| US-12612440-B2 | Modified bovine G-CSF polypeptides and their uses | AARS1, NPEPPS, GLUL | RNPEP 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.